Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.

Researchers say the data further support the use of an FFR-first strategy in treating intermediate coronary lesions.

The findings hint at why the ABYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...